antibody

Goat anti Apo B-48/100

MBS315585

1 ml

455 USD

polyclonal

goat

nonconjugated

western blot, ELISA, enzyme immunoassay

Antibody

Goat anti Apo B-48/100

Apolipoprotein B-48/100 (Apo B-48/100)

Goat Antibody to Human Apolipoprotein B-48/100 (Apo B-48/100)

apolipoprotein B-100; Apolipoprotein B-100; apolipoprotein B-100; apoB-48; apoB-100; apo B-100; mutant Apo B 100; OTTHUMP00000115994; apolipoprotein B48; apolipoprotein B (including Ag(x) antigen)

APOB; APOB; FLDB; LDLCQ4

APOB_HUMAN

Polyclonal

Goat

4563

Apolipoprotein B-48/100 (Apo B-48/100). Binds to Apo B-48/100.

Human LDL-Sepharose Affinity column and conjugated with biotin

Biotin, Liquid

1mg/ml

Short-term (up to 1 week) store at 2 to 8 degree C. Long term, aliquot and store at -20 degree C.

EIA/ELISA, Western Blot

Can be used for detection of Apo B-100 in plasma and lipoproteins for immunoassay and immunoblot. Dilution range for immunoblot and ELISA range: 1:5,000-1:40,000. Each laboratory should determine an optimum working titer for use in its particular applicat

Immunogen: Human LDL

Buffer: 10mM PBS, 0.15M Sodium chloride, 1mM EDTA pH 7.2 containing 10mg/ml BSA. Preservative: 0.02% Sodium azide. Lyophilized: Yes. Important Note: Centrifuge before opening to ensure complete recovery of vial contents. Warnings: This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1 - 1.0%. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.

Polyclonal Antibodies to Lipoproteins

Herscovitz, H., et al., (2001), "The N-terminal 17% of ApoB binds tightly and irreversibly to emulsions modeling nascent very low density lipoproteins" J. Lipid Res., 42: 51-59. Kitchens, R.L., et al., (2003), "Acute inflammation

105990532

NP_000375.2

NM_000384.2

P04114

515,605 Da

Cell Surface Interactions At The Vascular Wall Pathway 106062!!Chylomicron-mediated Lipid Transport Pathway 106157!!FOXA1 Transcription Factor Network Pathway 137979!!Fat Digestion And Absorption Pathway 194385!!Fat Digestion And Absorption Pathway 194324!!Formation Of Platelet Plug Pathway 106029!!Hemostasis Pathway 106028!!LDL-mediated Lipid Transport Pathway 106159!!Lipid Digestion, Mobilization, And Transport Pathway 106111!!Lipoprotein Metabolism Pathway 106156

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq]

Function: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Subcellular location: Secreted. Induction: Up-regulated in response to enterovirus 71 (EV71) infection (at protein level). Ref.34. Post-translational modification: Palmitoylated; structural requirement for proper assembly of the hydrophobic core of the lipoprotein particle. Ref.31. Involvement in disease: Defects in APOB are a cause of hypobetalipoproteinemia familial type 1 (FHBL1) [. MIM:107730]. A disorder characterized by highly reduced plasma concentrations of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia. Ref.46Defects in APOB are a cause of familial ligand-defective apolipoprotein B-100 (FDB) [. MIM:144010]. FDB is a dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors. Ref.40 Ref.42 Ref.44Note=Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Sequence similarities: Contains 1 vitellogenin domain. RNA editing: Edited at position 2180.The stop codon (UAA) at position 2180 is created by RNA editing. Apo B-48, derived from the fully edited RNA, is produced only in the intestine and is found in chylomicrons. Apo B-48 is a shortened form of apo B-100 which lacks the LDL-receptor region. The unedited version (apo B-100) is produced by the liver and is found in the VLDL and LDL. Sequence caution: The sequence AAA51752.1 differs from that shown. Reason: Frameshift at positions 942, 951, 1139, 1165, 1164, 1371 and 1385.

1 ml

455 USD